AbbVie shares jump as stock buying pressure builds

Traders Union
All News
Financial News
Abbvie surges 3.33% today on momentum

Highlights

AbbVie agreed to acquire Apogee Therapeutics for approximately $10.9 billion, expanding its immunology pipeline in atopic dermatitis and asthma.
The company secured European Commission approval of Skyrizi for pediatric plaque psoriasis and continues to generate robust free cash flow above revenue expectations.
AbbVie is trading near highs with strong bullish momentum, overbought signals, and an expected five-day price range of $235 to $250.99.

Immunology expansion and regulatory wins drive bullish investor sentiment

AbbVie has reached an agreement to acquire Apogee Therapeutics for about $10.9 billion in cash to strengthen its immunology portfolio with assets in atopic dermatitis and asthma. The European Commission has approved Skyrizi for pediatric patients with moderate-to-severe plaque psoriasis. AbbVie also declared a quarterly cash dividend of $1.73 per share and continues to deliver strong free cash flow following quarterly earnings that exceeded revenue expectations.

Anton Kharitonov, expert at Traders Union, points out that although AbbVie trades above all key moving averages, the recent surge appears heavily driven by acquisition headlines rather than sustainable fundamentals. He notes several technical overbought signals, such as an RSI above 66 and a crowded CCI, which raise the risk of a reversal. Kharitonov remains cautious on the durability of buyer momentum, especially with volatility rising and bullish sentiment stretched. Institutional moves like the dividend and regulatory approvals do provide some downside cushion, but he sees limited near-term reward for new buyers. "I expect heightened risk of a pullback toward $237.36 as overbought signals intensify and news momentum fades."

Viktoras Karapetjanc, expert at Traders Union, sees strong upside potential following AbbVie's strategic acquisition of Apogee Therapeutics. He emphasizes expanding immunology assets, robust free cash flow, and a growing dividend as pillars supporting the bullish structure. Karapetjanc believes the technical picture confirms sustained buyer interest, with further growth possible if resistance at $243.2 is cleared. He expects continued positive sentiment as new approvals and earnings momentum drive institutional demand. "With the uptrend well-supported and key catalysts in play, I see ABBV poised for further gains within the $235 to $250.99 range."

Buyer dominance persists amid overbought signals and elevated volatility

AbbVie is trading above its 20-day, 50-day, and 200-day moving averages ($222.84, $213.23, and $220.88 respectively), signaling sustained strength in the short, medium, and long term. Immediate technical levels place resistance at $243.2 and support at $237.36, with Ichimoku Kijun support at $222.43 supporting the bullish structure. Momentum signals are largely positive: MACD shows continued upward movement, ADX indicates neutral trend strength, and RSI registers a moderately overbought reading at 66.09. Both Stochastic RSI and Commodity Channel Index are overbought, while Bull/Bear Power at 11.59 points to strong buyer dominance, backed by a supportive Awesome Oscillator. The stock has gained $7.82 intraday amid elevated volatility and buyer-driven momentum.

Earlier, analysts noted that AbbVie was exhibiting sustained technical strength, though warning that overbought momentum could lead to near-term consolidation. With the company's major acquisition of Apogee Therapeutics and continued positive developments, traders should now focus on whether bullish momentum can drive a breakout above $243.2 to extend the uptrend beyond anticipated resistance.

Source of Data: ABBV Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.